Utility & Futility of Liver Transplantation in ACLF: When to Draw a Line?

Utility & Futility of Liver Transplantation in ACLF: When to Draw a Line?

Summary of Lecture by K. Rajender Reddy, MD | Presented at DDW, Washington DC

1. Main Clinical Topics Discussed

• Definition, staging, and epidemiology of Acute-on-Chronic Liver Failure (ACLF)
• Precipitating events and pathophysiology of ACLF
• Role of liver transplantation (LT) in ACLF: patient selection, outcomes, and futility
• Delisting patterns and reasons for transplant ineligibility
• ICU transplantation outcomes and program accountability considerations

2. Key Learning Points, Guidelines, and Recommendations

Definition & Classification:

• ACLF is a distinct syndrome from acute liver failure or simple decompensated cirrhosis — it represents a subgroup of cirrhotic patients developing acute organ failure with high short-term mortality
• Three major classification systems exist with ongoing challenges in unification:

- NACSELD (North American Consortium for the Study of End-Stage Liver Disease)

- EASL-CLIF (European): Grade 1 = single organ failure; Grade 2 = two organ failures; Grade 3 = ≥3 organ failures

- APASL (Asia-Pacific)

• Higher ACLF grade correlates directly with increasing mortality

Transplant Selection Principles:

• LT outcomes are best in ACLF Grade 1–2; Grade 3 carries significantly compromised post-transplant survival
• Patients on vasopressors or mechanical ventilation (circulatory/respiratory failure) have markedly worse outcomes
• Non-circulatory, non-respiratory organ failures (e.g., acute kidney injury, hepatic encephalopathy) are more favorable for transplant candidacy
• ICU-based ACLF patients are generally not considered transplant candidates at high-volume centers due to poor outcomes and program accountability standards
• Resolution of ACLF prior to transplantation is associated with superior post-transplant survival

3. Specific Clinical Data, Statistics, and Study Results Cited

Epidemiology:

• ~600,000 individuals in the US have cirrhosis at any given time
• ACLF prevalence: 10–30% among hospitalized cirrhotic patients
• Average hospital stay: 16 days (ACLF) vs. 7 days (non-ACLF)
• ACLF short-term mortality: 50–60%
• Hospitalizations and associated costs are steadily increasing

NACSELD Delisting Study (n=413 cirrhotic patients with infection):

• 277 patients were not listed for LT
• 136 patients were listed for LT within 6 months of infection
• 42% of listed patients were delisted or died within 6 months
• 47 patients were successfully transplanted within 6 months
• Primary reason for delisting: infection-related ACLF (most common), followed by HCC progression or cardiovascular comorbidities
• With >2 organ failures: 38% delisting or death rate; only 11% successfully transplanted

Single-Center ACLF Outcomes Study:

• No ACLF resolution + no LT → 90-day mortality: 75%
• No ACLF resolution + LT → 1-year survival: 75%
• ACLF resolution + subsequent LT (n=10) → 1-year survival: 90%

UNOS Database (ICU vs. Non-ICU Transplant Outcomes, 10-year analysis):

• ICU-transplanted patients vs. home/hospital-transplanted:

- 3-month mortality: higher in ICU group

- 12-month mortality: 23% (ICU) — equating to ~77% 1-year survival

- Progressive mortality increase from 14% (3 months) to 23% (12 months) attributed to ongoing frailty, sarcopenia, recurrent infections, and repeated hospitalizations

Precipitating Events (Regional Variation):

• Western/US: Bacterial infections predominate